TRex Bio (NASDAQ:TRXB) Major Shareholder Alexandria Venture Investments Buys 178,571 Shares of Stock

TRex Bio, Inc. (NASDAQ:TRXB) major shareholder Alexandria Venture Investments purchased 178,571 shares of TRex Bio stock in a transaction that occurred on Tuesday, October 13th. The stock was bought at an average cost of $14.00 per share, with a total value of $2,499,994.00. Following the completion of the transaction, the insider owned 1,346,501 shares of the company’s stock, valued at $18,851,014. The trade was a 15.29% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

TRex Bio Price Performance

Shares of TRXB opened at $14.16 on Friday. TRex Bio, Inc. has a 12-month low of $13.21 and a 12-month high of $15.50.

TRex Bio Company Profile

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.